Kirk Randal J
recently revealed that they own 4.9% of Soligenix Inc. (NASDAQ:SNGX) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission on Friday, June 16th. The investor owns 277,631 shares of the stock valued at about $560,815. The reporting parties listed on the disclosure included Randal J Kirk, Irs Identification No: 541923091, Irs Identification No: 271471440 and Irs Identification No: 260084895. The filing is available through the SEC website at this link.
Kirk Randal J
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Shares of Soligenix Inc. (NASDAQ:SNGX) traded down 2.42% during trading on Friday, reaching $2.02. 67,125 shares of the company were exchanged. The firm’s market capitalization is $11.46 million. Soligenix Inc. has a 1-year low of $2.02 and a 1-year high of $14.40. The company’s 50-day moving average is $2.53 and its 200 day moving average is $2.61.
Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Thursday, May 11th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.02. Soligenix had a negative net margin of 41.74% and a negative return on equity of 102.83%. The business had revenue of $1.30 million for the quarter. Equities research analysts expect that Soligenix Inc. will post ($0.63) EPS for the current fiscal year.
Separately, Maxim Group set a $4.00 target price on shares of Soligenix and gave the company a “buy” rating in a report on Monday, May 22nd.
In other news, major shareholder Randal J. Kirk sold 160,968 shares of the stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $3.12, for a total transaction of $502,220.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.09% of the stock is currently owned by company insiders.
Soligenix Company Profile
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Want to see what other hedge funds are holding SNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soligenix Inc. (NASDAQ:SNGX).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/kirk-randal-j-owns-4-9-stake-in-soligenix-inc-sngx/1916607.html
Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.